Contemporary Pharmacotherapy for OAB 2022: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2022)

Much has been written and debated about drug treatment of overactive bladder (OAB) over the past 2 decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation, and innovation. The publication of the recently updated AUA/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline entitled, “Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults,” and the proceedings of the 7th International Consultation on Incontinence, as well as European Association of Urology (EAU) Guidelines have maintained considerable interest in this area amongst researchers and practitioners. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder, review currently available agents and discuss agents in development.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

AbbVie
Astellas
Medtronic
Urovant Sciences, Inc.

 

Target Audience

  • Urologists
  • Residents

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Define the similarities and differences between the various oral pharmacotherapies for OAB.
  2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.
  3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
  4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
  5. Discuss potential future pharmacological pathways and therapies for OAB.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
05/18/2022
Course expires: 
05/18/2023
Rating: 
0

Education Council Disclosures

 Education Council Disclosures 2021

COI Review Work Group Disclosures

 COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Eric Rovner, MD

has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Hologix;.
has a financial relationship (Investment Interest (Specialty Not Specified)) with NextMed;.
has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with astellas;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Allergan;.
has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Valencia;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Urovant;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with NIH/NIDDK;.
has a financial relationship (Scientific Study or Trial (Female Pelvic Medicine & Reconstructive Surgery)) with uromedica;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Bluewind;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Medtronics;.
Faculty(s)

Christopher Chapple

has a financial relationship (Scientific Study or Trial (General Urology)) with Allergan;.
has a financial relationship (Meeting Participant or Lecturer (General Urology)) with Luoin Pharma;.
has a financial relationship (Consultant or Advisor (General Urology)) with Ferring;.
has a financial relationship (Consultant or Advisor (General Urology)) with Takeda;.
has a financial relationship (Scientific Study or Trial (General Urology)) with Bayer Schering Parma AG;.
has a financial relationship (Scientific Study or Trial (General Urology)) with Astellas;.
has a financial relationship (Consultant or Advisor (General Urology)) with Allergan;.
has a financial relationship (Consultant or Advisor (General Urology)) with Pierre Fabre;.
has a financial relationship (Consultant or Advisor (General Urology)) with Symimetics;.
has a financial relationship (Health Publishing (General Urology)) with Ferring;.
has a financial relationship (Meeting Participant or Lecturer (General Urology)) with Astellas;.
has a financial relationship (Health Publishing (General Urology)) with Astellas;.
has a financial relationship (Consultant or Advisor (General Urology)) with Contura;.
has a financial relationship (Consultant or Advisor (General Urology)) with Urovant Sciences;.
has a financial relationship (Scientific Study or Trial (General Urology)) with Ferring;.
has a financial relationship (Health Publishing (General Urology)) with Bayer Schering Parma AG;.
has a financial relationship (Meeting Participant or Lecturer (General Urology)) with Allergan;.
has a financial relationship (Leadership Position (General Urology)) with European Association of Urology;.
has a financial relationship (Scientific Study or Trial (General Urology)) with Poesis Medical;.
has a financial relationship (Consultant or Advisor (General Urology)) with Bayer Schering Parma AG;.
has a financial relationship (Consultant or Advisor (General Urology)) with Astellas;.

Alan Wein, MD

has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Valencia;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Urovant;.
has a financial relationship (Consultant or Advisor (General Urology)) with Antares;.
has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Medtronic;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by viewing the webcast, completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2022
Expiration Date: May, 2023

ACCREDIDATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group. 
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning 
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES

DISCLAIMER:

 The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

CONSENT TO USE OF PHOTOGRAPHIC IMAGES:

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

REPRODUCTION PERMISSION:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/ DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.